Skip to content
buyModerate cluster of 3

William Benton Jones bought $16k of CRVS

See Remarks at Corvus Pharmaceuticals, Inc.. 20,000 shares at an average of $0.79, traded Dec 20, 2022, filed Dec 20, 2022.

Conviction score
41
Value
$16k
20,000 shares
Holdings after
133,773
+18% from before
From 52-week low
+10%
low $0.71, close $0.78
From 52-week high
-71%
high $2.73, as of Dec 20, 2022

Score components

  • Role
    Officer
    +15
  • Trade size
    $16k at market
    0
  • Relative to holdings
    Holdings up 18%
    +3
  • Price context
    71% below the 52-week high
    +8
  • Cluster
    3 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CRVSOct 13, 2026 · close 9.41
Since filing Dec 20, 2022: +1106.4%SPY +114.3% · excess +992.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001567619-22-021876, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 20, 2022POpen-market purchase
Common Stock
+20,000$0.79$16k133,773Dec 20, 2022

Related signals

Other insiders at Corvus Pharmaceuticals, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
44Moderate
CRVSbuy
Corvus Pharmaceuticals, Inc.
David Scott Moore
director
$250k
21,700 shares
-
37Weak
CRVSbuy
Corvus Pharmaceuticals, Inc.
Richard A Miller Md
President and CEO
$83k
6,932 shares
+1%
53Moderate
CRVSsell 2
Corvus Pharmaceuticals, Inc.
Peter A. Thompson
director, owner
$4.9M
1,176,332 shares
-14%
53Moderate
CRVSsell 2
Corvus Pharmaceuticals, Inc.
Orbimed Advisors LLC
director, owner
$4.9M
1,176,332 shares
-14%
74Notable
CRVSbuy 2
Corvus Pharmaceuticals, Inc.
Richard A Miller Md
President and CEO
$1000k
577,634 shares
-
40Moderate
CRVSbuy 2
Corvus Pharmaceuticals, Inc.
William Benton Jones
See Remarks
$35k
20,000 shares
+15%
64Notable
CRVSbuy 3
Corvus Pharmaceuticals, Inc.
Richard A Miller Md
President and CEO
$45k
60,000 shares
+4%
66Notable
CRVSbuy 3
Corvus Pharmaceuticals, Inc.
Leiv Lea
Chief Financial Officer
$26k
34,000 shares
+34%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

William Benton Jones bought $16k of CRVS | InsiderTell